Introduction
EGFR is expressed in a majority of human carcinomas and its frequent overexpression, activation, and mutations in tumors are often associated with aggressive cancer phenotypes (1) . Two major classes of EGFR-targeting agents have been developed including tyrosine kinase inhibitors, such as gefitinib and erlotinib, which competitively bind to the ATP pocket of EGFR (2) , and mAbs, including cetuximab and panitumumab, that bind domain III of EGFR and inhibit ligand binding (3, 4) . Despite the success of this class of EGFR antagonists, they are associated with on-target toxicity, most notably a severe papulopustular rash thought to be the consequence of disruption of normal EGFR function in skin (5) .
MAb 806 is a novel anti-EGFR antibody that selectively targets a unique epitope of the EGFR which is largely inaccessible when EGFR is expressed at normal physiological levels (6, 7) . The targeted epitope is accessible in tumors with wild-type EGFR amplification or in tumors that express EGFRvIII, the most common deletion mutant of EGFR that lacks the ligand-binding domain of exons 2-7 and retains constitutive kinase activity (8) (9) (10) . Thus mAb806 has tumor-specific binding properties and would not be expected to elicit the side effects, including skin rash, observed with other cetuximab-like EGFR targeting (mAbs) associated with targeting of normal tissues. Consistent with these expectations, in a phase 1 trial a radiolabeled chimeric version of mAb806 (ch806) demonstrated tumor uptake in multiple tumor types with minimal evidence of normal tissue uptake (11) .
To reduce the risk of immunogenicity and enable clinical development we humanized mAb 806e to generate ABT-806, a recombinant IgG1/kappa mAb. In a Phase 1 study in patients with advanced solid tumors, ABT-806 was well tolerated, with a very low level of cutaneous toxicity and linear pharmacokinetics indicating the absence of extensive EGFR binding in normal tissues (12) .
Here we characterize the binding and functional characteristics of ABT-806 including assessment of pharmacodynamic tumor changes in total EGFR tyrosine phosphorylation in response to ABT-806. We compared the activity of ABT-806 to cetuximab against different human tumor xenografts, including patient-derived xenograft (PDX) models, and correlated outcomes with EGFR expression and genotype.
Since its safety profile suggests that ABT-806 may be more amenable to higher dosing and combination with chemotherapy than are other EGFR-directed therapies, combinations with standard of care (SOC) therapy were also investigated. The limited normal tissue binding properties of ABT-806 also permitted evaluation of [
111
In]ABT-806 tumor uptake in mouse xenograft models to validate its use as a novel molecular imaging technique for patient selection and to investigate the relationship between ABT-806 dose and receptor occupancy.
Materials and Methods

Antibodies and reagents
The soluble ECDs of EGFR were expressed from transiently transfected HEK293 cells as secreted proteins (inclusive of signaling peptide 1-24 that is cleaved during secretion) with a C-terminal LESRGPF-Myc-NMHTG-6His and purified by Ni-IMAC and SEC. Details of EGFR protein forms were plated at 2 μg/mL for 1 hour at room temperature with shaking. After three washes ABT-806 and cetuximab were added at 50 μg/mL and 3 μg/mL, respectively, and 1:3 serial dilutions were prepared.
Test antibody was incubated in a 100 μL final volume for 1 hour at room temperature with shaking.
Following three washes a secondary goat anti-human IgG-HRP antibody (Thermo Scientific Pierce) was added at 100μL/well and incubated for 1 hour at room temperature with shaking. Plates were washed three times and developed using 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Thermo Scientific Pierce). The reaction was stopped with 1N phosphoric acid and OD 450 signal was measured using a SpectraMax (Molecular Devices). ) protein forms (analytes) binding to anti-EGFR mAbs (ligands). The assay format was Fc-based capture via immobilized anti-human (Fc) antibody (Thermo Scientific Pierce). A standard amine coupling protocol was used to immobilize the capture reagents via primary amines to the carboxy-methyl (CM) dextran surface of CM5 sensor chips according to the manufacturer's instructions (Biacore Life Sciences).
For binding kinetics measurements the assay buffer was HBS-EP+ (Biacore Life Sciences): 10 mM Hepes (pH 7.5), 150 mM NaCl, 3 mM EDTA, 0.05% P20. During the assay all measurements were referenced against the capture surface alone. Each assay cycle consisted of the following steps: (1) Ligand capture;
(2) Analyte injection over both reference and test surface, 240 μL at 80 μL/min, after which the dissociation was monitored for 15 min at 80 μL/min; and (3) Regeneration of capture surface with low pH glycine. For kinetic determinations, analyte injections were randomized 3-fold dilution series from 3mM -12.35nM. Buffer only injections were included for secondary referencing. Data were processed and fit to a 1:1 binding model using Biacore T100 Evaluation Software to determine the binding kinetic rate constants, k a (on-rate) and k d (off-rate), and the K D (equilibrium dissociation constant, also referred to as "affinity").
In vivo studies
All animal studies were reviewed and approved by AbbVie's Lake County Institutional Animal Care and Use Committee. Animal studies were conducted in an AAALAC accredited program and veterinary care was available to ensure appropriate animal care. Mice were group-housed 10 per cage with food and water available ad libitum and were acclimated to the animal facilities for a period of at least one week prior to initiation of experiments.
Tumor cells were mixed with 50% Matrigel (BD Biosciences) and injected s.c. into the flank of 6-to 8-week old female mice (Charles River Laboratories) as described: SCC15 cells were injected at 1x10 Tumors were allowed to grow to a predetermined size, at which time mice were allocated by tumor volume into study groups (n = 10 mice/group) so that the mean tumor volumes of the groups were statistically similar. Mice were then entered into the dosing phase of the study (described below). The PDX tumors were randomly assigned into study groups (n = 7-9 mice/group) when the individual tumors reached ~250 mm 
Western blot analysis
Cell lysates (10 μg) were resolved by SDS-PAGE using 4-12% Bis-Tris midi gels (Invitrogen, catalog no. WG1402BX10) and transferred to nitrocellulose membranes using an iBlot Dry Transfer System In into DTPA-antibody, and no post-labeling purification was needed.
SPECT/CT imaging
A SPECT scanner with a built-in CT dedicated to small animal imaging was used (nanoSPECT/CT, BioScan). The nanoSPECT contains four detectors; each fitted with a tungsten collimator and a ninepinhole aperture for increased spatial resolution (<1 mm) and detection sensitivity. Tumors were sizematched using calipers to ensure comparable tumor sizes within each experimental group of mice. After injection of [ 
Results
Characterization ABT-806 binding properties
A series of binding assays were performed to characterize the binding of ABT-806 to recombinant EGFR.
In an ELISA format ABT-806 exhibits higher binding to EGFRvIII and EGFR1-501, while these latter two forms differ in off-rates only.
These observations are consistent with the EGFRvIII having unique epitope exposure ( Table 1 ). The U87MGde2-7 cells similar to the binding observed for cetuximab ( Figure 1C ). Both ABT-806 and cetuximab displayed limited binding to parental U87MG cells which express low levels of wild-type EGFR ( Figure 1D ).
ABT-806 in vivo potency in EGFRvIII expressing glioblastoma multiforme tumors
The binding characteristics of ABT-806 suggest that it may be effective against tumors expressing EGFRvIII. Since glioblastoma multiforme (GBM) has a high frequency of EGFRvIII expression, the activity ABT-806 was compared to cetuximab in the U87MGde2-7 GBM model. This tumor model was engineered to express EGFRvIII as cell lines do not maintain expression of endogenous EGFRvIII (17, 18) . Growth of U87MGde2-7 tumors was significantly inhibited by ABT-806 treatment (Figure 2A ). In contrast, cetuximab showed only minimal activity in this model even at the 40 mg/kg high dose level tested (Figure 2A ).
These studies were extended to the evaluation of ABT-806 activity against the EGFRvIII positive PDX model SN0199. GBM PDX models like SN0199, unlike standard cell line xenograft models, can maintain expression of endogenous EGFRvIII and thus may be more clinically relevant than standard cell line derived xenografts (17, 19, 20) . Due to the variable growth rate of the implanted PDX tumors, these studies were performed with an accrual design with data presented as a Kaplan-Meier plot. A 10 mg/kg dose of cetuximab was selected as the comparator since the exposures achieved with this dose would be expected to exceed those achievable in patients (21). In contrast ABT-806 was assessed at doses of both 10 and 40 mg/kg (dosed 3 times a week for 2 weeks) since reduced normal tissue binding of ABT-806 compared to cetuximab has been demonstrated thereby allowing higher tolerated doses in patients. As shown in Figure 2B 
ABT-806 in vivo potency in squamous cell carcinoma tumor models expressing wild-type EGFR
ABT-806 binding properties and published results with mAb 806 and ch806 suggested that ABT-806 may also be effective against tumor cells overexpressing wild-type EGFR (6, 13, 16) . Since EGFR is frequently overexpressed in squamous tumors, the antitumor efficacy of ABT-806 was compared to cetuximab in the A431 squamous xenograft model that expresses amplified EGFR (22) . Despite poor in vitro binding and an inability to inhibit signaling of wild-type EGFR expressing cells (data not shown), ABT-806 dosed at 10 mg/kg three times per week for 2 weeks exhibited comparable activity to cetuximab dosed in an equivalent manner ( Figure 3A) . At higher doses (40 mg/kg) cetuximab was more effective at inhibiting tumor growth than was ABT-806 dosed (87% TGI for cetuximab and 58% TGI for ABT-806 on day 30; Figure 3B ). These results suggest that higher exposures of ABT-806 relative to cetuximab may be required to achieve similar efficacy and are consistent with the higher affinity binding of cetuximab to wild-type EGFR (Table 1) .
ABT-806 was also highly effective in a head and neck squamous cell carcinoma (HNSCC) xenograft model SCC15 that overexpresses wild-type EGFR ( Figure 3C ). ABT-806 treatment resulted in tumor 
regressions although higher dosing was required to show activity comparable to that seen with cetuximab ( Figure 3C ).
ABT-806 down regulates wild-type EGFR and pEGFR in vivo
In order to investigate the mechanism of ABT-806-mediated tumor growth inhibition in wild-type EGFR 
ABT-806 combinations with chemotherapy
The safety profile of ABT-806 makes it an attractive candidate for combination with chemotherapy in the treatment of EGFR positive malignancies. In order to test this premise ABT-806 in combination with different chemotherapy agents was assessed in both wild-type EGFR and EGFRvIII expressing tumor Cetuximab is FDA-approved for use in combination with cisplatin and 5FU in recurrent or metastatic HNSCC, so these combinations with ABT-806 were evaluated in the wild-type EGFR expressing HNSCC tumor model SCC15 (23) . Because ABT-806 was highly potent as monotherapy in this model ( Figure   2C ), it was dosed at a suboptimal level (10 mg/kg) to assess its ability to enhance activity of SOC therapy.
The combination of ABT-806 and cisplatin ( Figure 5A ) or ABT-806 and 5FU ( Figure 5B ) was more effective in inhibiting SCC15 tumor growth than were any of the agents tested individually. Increased anti-tumor activity was also observed when ABT-806 was combined with both cisplatin and 5FU ( Figure   5C ).
The ability of ABT-806 to combine with SOC chemotherapy was also evaluated in the EGFRvIII expressing U87MGde2-7 xenograft model. The current SOC therapy for newly diagnosed glioblastoma following surgical debulking is radiation therapy (RT) in combination with temozolomide (TMZ) (24, 25) . ABT-806 was dosed at10 mg/kg in this model to enable evaluation of combination effects. Addition of ABT-806 to RT resulted in a modest increase in tumor growth inhibition (data not shown); however, the addition of ABT-806 to TMZ produced pronounced increase in tumor growth inhibition ( Figure 5D ). 
Specific tumor uptake and receptor occupancy measurements using [
Discussion
ABT-806 binds to EGFRvIII with high affinity and exhibits potent anti-tumor activity both against glioblastoma cell line and patient-derived xenograft models that express this form of the receptor.
Patient-derived xenograft models may more accurately recapitulate the cellular heterogeneity, architectural and molecular characteristics of the primary human tumor compared to standard cell linepassaged xenograft models (26) . PDX models are particularly relevant for assessing EGFRvIII expressing tumors since standard GBM tumor cell lines show loss of EGFRvIII expression during passage in cell culture (17) (18) (19) . In contrast to ABT-806, cetuximab binds to EGFRvIII with similar affinity but does not inhibit signaling and showed little or no activity in the EGFRvIII expressing xenograft and PDX models. The different epitopes that these antibodies recognize underlie their distinct mechanisms of action and consequent efficacies against human xenograft tumors overexpressing EGFRvIII. Previous studies suggest that binding to the ABT-806 epitope blocks receptor dimerization and subsequent activation (8) . In contrast, cetuximab exerts its anti-tumor activity, at least in part, by binding to its epitope on domain III of the EGFR preventing ligand binding (27) . Since EGFRvIII is constitutively active, cetuximab does not directly block signaling from this receptor. In support of this conclusion ABT-806, but not cetuximab, blocked EGFRvIII phosphorylation in vitro and in vivo.
EGFR is overexpressed in approximately 50% of primary GBM patients (28) 
U87MGde2-7 tumor model. The ability of ABT-806 to cross the blood brain barrier and specifically target glioblastoma in patients is supported by the selective imaging of [
111
In]ABT-806 in a GBM orthotopic mouse model. Phase 1 clinical observations with both radiolabeled ch806 and ABT-806 also indicate excellent uptake in GBM patients demonstrating that this antibody can effectively cross the BBB or that the BBB is sufficiently comprised in these patients to allow antibody uptake (11, 30) .
In contrast to its high affinity binding to EGFRvIII ABT-806 displays lower affinity binding to wild-type EGFR with non-saturable binding to cells overexpressing wild-type EGFR even at high concentrations.
Despite its low binding to wild-type EGFR, ABT-806 is efficacious in the wild-type EGFR expressing A431 and SCC15 squamous carcinoma xenograft models. The reason for efficacy against wild-type EGFR expressing tumor models in vivo despite low binding in vitro remains unknown but may be explained by an increased prevalence of the ABT-806 epitope in vivo. Although antibody effector functions may contribute to the antitumor activity, ABT-806 is also effective at inhibiting EGFR phosphorylation and downstream signaling in vivo, consistent with an anti-tumor effect by inhibition of EGFR signaling.
Cetuximab was more potent than ABT-806 at inhibiting tumor growth and downstream signaling in these EGFR wild-type in vivo models. An important consideration when extrapolating these preclinical results to human patients is that reduced normal tissue binding of ABT-806 compared to cetuximab has been demonstrated thereby allowing higher tolerated doses and subsequent higher plasma levels of ABT-806 in patients compared to cetuximab. This outcome is supported by Phase 1 studies in which ABT-806 dosed up to 24 mg/kg was well tolerated, with none of the characteristic EGFR-inhibitor skin toxicity observed (12, 30) . These results suggest that for tumors with high levels of EGFR expression, ABT-806 may 
